EP Patent

EP4021893A1 — Perk inhibiting compounds

Assigned to Hibercell Inc · Expires 2022-07-06 · 4y expired

What this patent protects

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.

USPTO Abstract

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4021893A1
Jurisdiction
EP
Classification
—
Expires
2022-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Hibercell Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.